Core Points - The employee stock ownership plan (ESOP) of Dazhenglin Pharmaceutical Group Co., Ltd. will expire on December 3, 2025 [1][2] - The ESOP was approved at the fourth extraordinary general meeting of shareholders in 2020 and has a duration of 36 months [1] - The board of directors has approved an extension of the ESOP for an additional 12 months, now set to expire on December 3, 2025 [2] Summary of Employee Stock Ownership Plan - The ESOP currently holds 6,572,239 shares, representing 0.58% of the company's total share capital [2] - The company has adhered to market trading rules and regulations during the ESOP period, ensuring no insider trading occurred [2] - Upon expiration of the ESOP, it will terminate automatically, and the management committee will handle the disposal of remaining rights in accordance with relevant regulations [2]

Group 1 - The company will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 6, 2025, from 15:00 to 16:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live streaming and online interaction [1][2] - Investors can submit questions for the briefing from May 29, 2025, to June 5, 2025, before 16:00 [3] Group 2 - Key participants in the briefing will include the General Manager, the Secretary of the Board, the Chief Financial Officer, and an Independent Director [2] - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [2] - After the briefing, investors can view the main content and outcomes of the event on the Shanghai Stock Exchange Roadshow Center website [3]

Core Viewpoint - The company has provided a guarantee of 600 million RMB for its subsidiaries to secure bank credit facilities, which is expected to support their operational needs and promote sustainable development [1][4]. Summary by Sections Guarantee Overview - The total guarantee amount provided by the company for its subsidiaries is 60,000 million RMB [1]. - The guarantee is a joint liability guarantee without any counter-guarantee [1]. - There are no overdue guarantees reported [1]. Subsidiary Information - The subsidiaries involved in the guarantee include: - Xinjiang Kangzhiyuan Pharmaceutical Co., Ltd. with a guarantee of 6,000 million RMB [1]. - Yili Kangzhiyuan Pharmaceutical Chain Co., Ltd. with a guarantee of 6,000 million RMB [1]. - Luoyang Dacarelin Pharmaceutical Co., Ltd. with a guarantee of 5,000 million RMB [1]. - Yingkou Fujuhe Pharmaceutical Chain Co., Ltd. with a guarantee of 3,000 million RMB [1]. - Xuchang Dacarelin Baoyuantang Pharmacy Chain Co., Ltd. with a guarantee of 2,000 million RMB [1]. - Maoming Dacarelin Chain Pharmacy Co., Ltd. with a guarantee of 27,000 million RMB [1]. - Xinyang Dacarelin Baixingfu Pharmaceutical Chain Co., Ltd. with a guarantee of 6,000 million RMB [1]. Financial Health of Subsidiaries - The subsidiaries have shown stable financial conditions, with total assets and liabilities as follows: - Xinjiang Kangzhiyuan: Total assets of 223.76 million RMB, liabilities of 200.03 million RMB, and net profit of 4.60 million RMB [2]. - Yili Kangzhiyuan: Total assets of 223.25 million RMB, liabilities of 175.11 million RMB, and net profit of 4.91 million RMB [2]. - Luoyang Dacarelin: Total assets of 408.73 million RMB, liabilities of 257.37 million RMB, and net profit of 14.47 million RMB [2]. - Yingkou Fujuhe: Total assets of 78.20 million RMB, liabilities of 49.33 million RMB, and net profit of 1.13 million RMB [2]. - Xuchang Dacarelin: Total assets of 90.55 million RMB, liabilities of 67.47 million RMB, and net profit of 1.37 million RMB [2]. - Maoming Dacarelin: Total assets of 1,992.40 million RMB, liabilities of 1,167.19 million RMB, and net profit of 131.63 million RMB [2]. - Xinyang Dacarelin: Total assets of 87.87 million RMB, liabilities of 45.28 million RMB, and net profit of 1.02 million RMB [2]. Necessity and Reasonableness of Guarantee - The guarantee is deemed necessary to meet the operational needs of the subsidiaries and aligns with the company's overall interests and development strategy [4]. - The subsidiaries are reported to have stable financial conditions and good creditworthiness, indicating their ability to repay the debts [4]. Cumulative External Guarantee - As of the announcement date, the total amount of guarantees signed after the 2024 annual general meeting authorization is 600 million RMB, accounting for 6.95% of the company's latest audited net assets [5]. - There are no overdue external guarantees or guarantees involving litigation reported [5].

证券代码：603233 证券简称：大参林 公告编号：2025-034 大参林医药集团股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 投资者可于 2025 年 5 月 29 日(星期四)至 6 月 5 日(星期四)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 DSL1999@dslyy.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 大参林医药集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日 发布公司 2024 年年度报告及 2025 年第一季度报告，为便于广大投资者更全面深 入地了解公司 2024 年度及 2025 年第一季度的经营情况及财务状况，公司计划于 2025 年 6 月 6 日下午 15:00-16:00 举行 2024 年度暨 2025 年第一季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以视频直播和网络互动形式召开，公司将针对 ...

证券代码：603233 证券简称：大参林 公告编号：2025-033 大参林医药集团股份有限公司 1、经公司 2020 年 10 月 9 日召开的第三届董事会第九次会议及 2020 年 10 月 26 日召开的 2020 年第四次临时股东大会，审议通过了《关于<大参林医药集 团股份有限公司 2020 年员工持股计划（草案）>及其摘要的议案》及相关议案， 同意实施公司 2020 年员工持股计划，股份来源于二级市场购买的公司股票。2020 年 11 月 25 日，公司召开了 2020 年员工持股计划第一次持有人会议，审议通过 了《关于设立员工持股计划管理委员会的议案》《关于选举公司员工持股计划管 理委员会委员的议案》《关于授权公司员工持股计划管理委员会办理本次员工持 股计划相关事宜的议案》，具体详见公司于 2020 年 11 月 26 日在上海证券交易所 网站（www.sse.com.cn）上披露的相关公告。本期员工持股计划的存续期为 36 个月，自公司公告最后一笔标的股票登记至员工持股计划名下之日起计算。 2、公司于 2023 年 8 月 18 日召开了 2020 年公司员工持股计划管理委员会 2023 年第一 ...

证券代码：603233 证券简称：大参林 公告编号：2025-032 大参林医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 担保 | 被担保人 | 担保金额 | 授信机构 | 担保类 | 反担保 | 期限 | | --- | --- | --- | --- | --- | --- | --- | | 人 | | （万元） | | 型 | 情况 | | | | 新疆康之源药业有限公 限责任公司 公司 | 6,000 | 招商银行股份有限公 | 连带责 | 无 无 | 以实际签署 | | | 司 | | 司乌鲁木齐分行 | 任担保 | | 的合同为准 | | | 伊犁康之源药业连锁有 | 6,000 | 招商银行股份有限公 | 连带责 | | 以实际签署 | | | | | 司乌鲁木齐分行 | 任担保 | | 的合同为准 | | | 漯河市大参林医药有限 | 5,000 | 广发银行股份有限公 | 连带责 | | 以实际签署 | | | | | 司洛阳分行 ...

Core Viewpoint - The competition among major platforms like Ele.me, JD.com, and Meituan in the food delivery sector has expanded into the pharmaceutical category, leading to a significant rise in the instant retail of medicines, with platforms investing in traffic resources, supply chains, and innovative marketing strategies [1][4]. Group 1: Market Dynamics - The instant retail of pharmaceuticals is experiencing rapid growth, becoming a crucial part of the outpatient pharmaceutical retail market [1][4]. - JD Health's "Buy Medicine in Seconds" feature has seen a threefold increase in order volume due to enhanced traffic resources [4][6]. - The instant retail sector is evolving from high-frequency to low-frequency demand, now covering a full range of categories, including pharmaceuticals [5][6]. Group 2: Platform Strategies - JD.com has prominently featured "24h Delivery of Medicines" on its app, enhancing visibility and traffic for its instant retail services [3][4]. - Meituan has launched its instant retail brand "Meituan Flash Purchase," further intensifying competition in the pharmaceutical retail space [4][6]. - Taobao's instant retail service has been upgraded to "Taobao Flash Purchase," which includes a significant category for purchasing medicines [3][4]. Group 3: Industry Trends - The transformation of physical pharmacies is driving the adoption of instant retail, as many pharmacies are closing, leading to a competitive environment where digital solutions are essential [7][8]. - The integration of online medical services with instant retail is creating a comprehensive service model for users, enhancing the purchasing experience [7][8]. - The collaboration among platforms, pharmaceutical companies, and pharmacies is deepening, allowing for more effective marketing and sales strategies [8][10]. Group 4: Financial Performance - One Heart Hall's new retail segment saw a 47.6% year-on-year increase in revenue, with the O2O instant retail channel contributing 78.2% [15][16]. - Yifeng Pharmacy reported online sales of 2.127 billion yuan in 2024, with 1.721 billion yuan coming from O2O, accounting for 80.9% of total online sales [16][17]. - The overall trend indicates that if online medical insurance is fully opened, the share of instant retail in physical pharmacies could rise to 32.1% by 2030 [16][17]. Group 5: Future Outlook - The competition for instant retail in pharmaceuticals among major platforms is expected to continue, with Douyin's unique position in social media marketing presenting both opportunities and challenges [18]. - The penetration of instant retail in lower-tier markets is anticipated to grow, making it a significant growth driver in the outpatient pharmaceutical retail market [18].

Core Viewpoint - The retail pharmacy industry in China is undergoing significant challenges, with a trend of store closures and a shift from aggressive expansion to a focus on quality and efficiency [3][4][10]. Group 1: Store Closures and Industry Trends - Major retail pharmacy chains, including Lao Bai Xing, Yi Feng Pharmacy, and Yi Xin Tang, have reported a continued strategy of closing underperforming stores while slowing down expansion efforts [3][4]. - In Q1 2025, Lao Bai Xing and Shu Yu Ping Min closed 161 and 86 stores respectively, while Yi Feng Pharmacy opened 94 stores but closed 84 [3][7]. - The overall closure rate in the retail pharmacy sector reached 5.7% in 2024, with over 39,000 stores shutting down [4][11]. Group 2: Financial Performance - Yi Feng Pharmacy reported Q1 2025 revenue of 600.9 million yuan, a year-on-year increase of 0.64%, while its net profit grew by 10.51% [7]. - In contrast, Lao Bai Xing, Yi Xin Tang, and Jian Zhi Jia experienced revenue declines of 1.88%, 6.53%, and 0.85% respectively in Q1 2025 [7][8]. - The financial performance of many listed pharmacy chains has shown a decline in both revenue and profit, indicating a challenging market environment [6][8]. Group 3: Market Dynamics and Future Outlook - The retail pharmacy industry is experiencing a consolidation phase, driven by increased market concentration and regulatory pressures [10][14]. - The shift from rapid expansion to a focus on closing unprofitable stores and improving operational efficiency is becoming a new trend in the industry [10][12]. - Companies are exploring new retail models and diversifying their offerings to adapt to changing market conditions, with some focusing on integrating online and offline sales [14][15].

Core Viewpoint - The retail pharmacy industry in China is facing significant challenges, leading to a wave of store closures and a shift in focus from rapid expansion to improving operational efficiency and quality [1][6][8]. Group 1: Store Closures and Expansion Strategies - Major retail pharmacy chains, including Lao Bai Xing, Yi Feng Pharmacy, and Yi Xin Tang, are continuing to close underperforming stores while slowing down their expansion efforts [1][4]. - In Q1 2025, Lao Bai Xing closed 161 stores and opened 24, while Yi Feng Pharmacy opened 94 stores (26 self-built and 68 franchises) but closed 84 [1][4]. - The overall closure rate for retail pharmacies reached 5.7% in 2024, with over 39,000 stores shutting down [1][6]. Group 2: Financial Performance - Financial reports for Q1 2025 show a mixed performance among major chains, with Lao Bai Xing, Yi Xin Tang, and Jian Zhi Jia experiencing revenue and profit declines [3][4]. - Yi Feng Pharmacy reported a revenue of 6.009 billion yuan, up 0.64% year-on-year, and a net profit of 449 million yuan, up 10.51% [3][4]. - Dazheng Lin achieved a revenue of 6.956 billion yuan, up 3.02%, and a net profit of 460 million yuan, up 15.45% [3][4]. Group 3: Industry Trends and Challenges - The retail pharmacy sector is undergoing a deep transformation, moving from aggressive expansion to a focus on quality and efficiency due to market saturation and increased regulatory scrutiny [6][8]. - The number of pharmacies in China increased from 524,000 in 2019 to 667,000 in 2023, leading to structural oversupply [8][9]. - Industry experts predict that around 20% of small pharmacies may be eliminated, further increasing market concentration [8]. Group 4: New Retail Strategies - Leading chains are integrating online and offline operations to adapt to changing market dynamics, with Yi Feng Pharmacy reporting significant online sales growth [9][10]. - Dazheng Lin is focusing on building a prescription transfer system and enhancing professional service capabilities to differentiate itself in a competitive landscape [9][10]. - Yi Xin Tang is exploring diversification into non-pharmaceutical products and new business models, such as combining pharmacies with convenience stores [10].

Meeting Overview - The shareholders' meeting of Dazhenglin Pharmaceutical Group Co., Ltd. was held on May 20, 2025, in Guangzhou [1] - The meeting was attended by shareholders representing 77.8557% of the total shares [1] - The meeting was conducted in accordance with the Company Law and the Articles of Association, with both on-site and online voting methods [1] Voting Results - All non-cumulative voting proposals were approved with high support from A-shareholders, including: - Proposal 1: 99.8008% in favor [1] - Proposal 2: 99.8015% in favor [1] - Proposal 3: 99.8009% in favor [1] - Proposal 4: 99.9882% in favor [1] - Proposal for the audit firm and internal control audit: 99.8592% in favor [1] Legal Compliance - The lawyers present confirmed that the meeting's procedures complied with relevant laws and regulations, ensuring the legality of the attendees and the voting process [3]